In August 2020, Global Outbreak and Alert and Response Network (GOARN) sent a request for assistance for epidemiologists to be deployed to the Democratic Republic of the Congo (DRC) to support the Ebola virus disease (EVD) outbreak response in the Equateur Province.
The number of reported human cases of illness caused by Campylobacter and Salmonella bacteria across Europe appears to have stabilised over the past five years, according to the latest report on zoonotic diseases by EFSA and ECDC.
As of 1 February 2021, European Union (EU) and European Economic Area (EEA) Member States and EU-neighbouring countries reported 336 locally-acquired human cases of West Nile virus infections in 2020. The last case of this transmission season was reported by the Netherlands in week 47.
As of 14 February 2021, seven cases of Ebola virus disease (EVD) have been reported in Guinea, including three deaths. Among these cases, three have been laboratory-confirmed at the national reference laboratory. Four cases remain in isolation at healthcare facilities.
As of 14 February 2021, four cases of Ebola virus disease (EVD), including two deaths, have been reported in the North Kivu province in the eastern part of the Democratic Republic of the Congo (DRC), where a large outbreak was declared over in June 2020. Two health zones are currently affected: Biena and Katwa.
On 18 November 2020, the 11th outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) was declared over. There have been 130 cases, including 55 deaths reported from 13 health zones in the Equateur Province since the beginning of the outbreak almost six months ago.
French authorities have reported an increased number of dengue cases in Martinique in recent months. The number of cases notified constitute the largest outbreak reported on the island in the last decade.
Based on a systematic literature review, ECDC assessed the efficacy, effectiveness and safety of newer and enhanced inactivated seasonal influenza (flu) vaccines among those 18 years or older. These assessed are MF59® adjuvanted, cell-based, high-dose, and recombinant haemagglutinin influenza vaccines.
The Flu Awareness Week is marked across the WHO European Region every year in October. It aims to raise awareness of the importance of vaccination for people’s health and well-being and to increase the uptake of seasonal influenza vaccination of people with underlying risk factors.
Organized by:World Health Organization (WHO) - Regional office for Europe